News | September 23, 2024
AstraZeneca Pharma India to launch Tremelimumab
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated
